An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.
Inhibitors of the protease of HIV-1 have been used successfully for the treatment of HIV-1-infected patients and AIDS disease. We tested whether these protease inhibitory drugs exerted effects in addition to their antiviral activity. Here, we show in mice infected with lymphocytic choriomeningitis v...
| Váldodahkkit: | , , , , , , , , , |
|---|---|
| Materiálatiipa: | Journal article |
| Giella: | English |
| Almmustuhtton: |
1998
|
| _version_ | 1826280707114139648 |
|---|---|
| author | André, P Groettrup, M Klenerman, P de Giuli, R Booth, B Cerundolo, V Bonneville, M Jotereau, F Zinkernagel, R Lotteau, V |
| author_facet | André, P Groettrup, M Klenerman, P de Giuli, R Booth, B Cerundolo, V Bonneville, M Jotereau, F Zinkernagel, R Lotteau, V |
| author_sort | André, P |
| collection | OXFORD |
| description | Inhibitors of the protease of HIV-1 have been used successfully for the treatment of HIV-1-infected patients and AIDS disease. We tested whether these protease inhibitory drugs exerted effects in addition to their antiviral activity. Here, we show in mice infected with lymphocytic choriomeningitis virus and treated with the HIV-1 protease inhibitor ritonavir a marked inhibition of antiviral cytotoxic T lymphocyte (CTL) activity and impaired major histocompatibility complex class I-restricted epitope presentation in the absence of direct effects on lymphocytic choriomeningitis virus replication. A potential molecular target was found: ritonavir selectively inhibited the chymotrypsin-like activity of the 20S proteasome. In view of the possible role of T cell-mediated immunopathology in AIDS pathogenesis, the two mechanisms of action (i.e., reduction of HIV replication and impairment of CTL responses) may complement each other beneficially. Thus, the surprising ability of ritonavir to block the presentation of antigen to CTLs may possibly contribute to therapy of HIV infections but potentially also to the therapy of virally induced immunopathology, autoimmune diseases, and transplantation reactions. |
| first_indexed | 2024-03-07T00:17:44Z |
| format | Journal article |
| id | oxford-uuid:7b706837-c6a8-4dd9-9ad6-8e712a62d7b2 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:17:44Z |
| publishDate | 1998 |
| record_format | dspace |
| spelling | oxford-uuid:7b706837-c6a8-4dd9-9ad6-8e712a62d7b22022-03-26T20:50:40ZAn inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7b706837-c6a8-4dd9-9ad6-8e712a62d7b2EnglishSymplectic Elements at Oxford1998André, PGroettrup, MKlenerman, Pde Giuli, RBooth, BCerundolo, VBonneville, MJotereau, FZinkernagel, RLotteau, VInhibitors of the protease of HIV-1 have been used successfully for the treatment of HIV-1-infected patients and AIDS disease. We tested whether these protease inhibitory drugs exerted effects in addition to their antiviral activity. Here, we show in mice infected with lymphocytic choriomeningitis virus and treated with the HIV-1 protease inhibitor ritonavir a marked inhibition of antiviral cytotoxic T lymphocyte (CTL) activity and impaired major histocompatibility complex class I-restricted epitope presentation in the absence of direct effects on lymphocytic choriomeningitis virus replication. A potential molecular target was found: ritonavir selectively inhibited the chymotrypsin-like activity of the 20S proteasome. In view of the possible role of T cell-mediated immunopathology in AIDS pathogenesis, the two mechanisms of action (i.e., reduction of HIV replication and impairment of CTL responses) may complement each other beneficially. Thus, the surprising ability of ritonavir to block the presentation of antigen to CTLs may possibly contribute to therapy of HIV infections but potentially also to the therapy of virally induced immunopathology, autoimmune diseases, and transplantation reactions. |
| spellingShingle | André, P Groettrup, M Klenerman, P de Giuli, R Booth, B Cerundolo, V Bonneville, M Jotereau, F Zinkernagel, R Lotteau, V An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. |
| title | An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. |
| title_full | An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. |
| title_fullStr | An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. |
| title_full_unstemmed | An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. |
| title_short | An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. |
| title_sort | inhibitor of hiv 1 protease modulates proteasome activity antigen presentation and t cell responses |
| work_keys_str_mv | AT andrep aninhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT groettrupm aninhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT klenermanp aninhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT degiulir aninhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT boothb aninhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT cerundolov aninhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT bonnevillem aninhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT jotereauf aninhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT zinkernagelr aninhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT lotteauv aninhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT andrep inhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT groettrupm inhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT klenermanp inhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT degiulir inhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT boothb inhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT cerundolov inhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT bonnevillem inhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT jotereauf inhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT zinkernagelr inhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses AT lotteauv inhibitorofhiv1proteasemodulatesproteasomeactivityantigenpresentationandtcellresponses |